Novel antibiotic active against gram-positive bacteria;Nuevos antibióticos activos frente a grampositivos

Revista Espanola de Quimioterapia

Volumn 13, Issue 4, 2000, Pages 344-351

  Garcia Sanchez J E ^a   Fresnadillo Martinez M J ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CEPHALOSPORIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ALPHA HEMOLYTIC STREPTOCOCCUS; BACILLUS; BACTERIAL INFECTION; CORYNEBACTERIUM; EDUCATION PROGRAM; GRAM POSITIVE BACTERIUM; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; LEUCONOSTOC; NONHUMAN; PROPHYLAXIS; REVIEW; SANITATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PEPTIDES; QUINOLINES;

EID: 0034491998     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. El resurgimiento de los grampositivos: Razones, significado clínico y posibilidades de control
2. Epidemiology of drug resistance. Implications for a post-antimicrobial era
3. Terapia antimicrobiana y medicina basada en la evidencia
4. Management of infections due to antibiotic-resistant Streptococcus pneumoniae
5. Antimicrobial resistance of 1113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
6. Impact of antibiotic resistance on chemotherapy for pneumococal infections
7. Management of community-acquired pneumonia in the era of pneumococcal resistance
8. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
9. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: Results of a Spanish multicentre study in 1998. Spanish group for the study of infection in the primary health care setting
10. A global gene pool for high-level cephalosporin resistance in commensal Streptococcus species and Streptococcus pneumoniae
11. Emergence of teicoplanin-resistant coagulase-negative staphylococci
12. European glycopeptide susceptibility survey of gram-positive bacteria for 1995
13. Proficiency of clinical laboratories in Spain in detecting vancomycin-resistant Enterococcus spp.
14. Estudio multicéntrico de resistencias en enterococos. Papel de la teicoplanina
15. VRSA, VISA and GISA: The dilemma behind the name game
16. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics
17. Antibióticos cetólidos
18. The fluorquinolone antibacterials: Past, present and future perspectives
19. New uses for new and old quinolones and the challenge of resistance
20. Development of daptomycin for Gram-positive infections
21. Moxifloxacin: A new antibiotic designed to treat community-acquired respiratory tract infections. A review of microbiologic and pharmacokinetic-pharmacodynamic characteristics
22. Moxifloxacin
23. Gatifloxacin
24. The evolving threat of antibiotic resistance in Europe: New data from Alexander Project
25. Decreased susceptibility of Streptococcus pneumoniae to flouroquinolones in Canada. Canadian Bacterial Surveillance Network
26. Will pneumococci put quinolones in their place?
27. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type 11 topoisomerase mutations and efflux to levels of resistance
28. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
29. Quinupristin/dalfopristin and linezolid: Where, when, which and whether to use?
30. Aspects practiques de la résistance aux antibiotics en médecine vétérinaire
31. Quinupristin/dalfopristin: Spectrum of activity, pharmacokinetics, and initial clinical experience
32. Quinupristin/dalfopristin: A novel selective-spectrum antibiotic for the treatment of multi-resistant and other Gram-positive pathogens
33. Mechanisms of resistance to quinupristin/dalfopristin among isolates of Enterococcus faecium from animals, raw meat, and hospital patients in western Europe
34. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants
35. Quinupristin-dalfopristin
36. Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721
37. Oxazolidinones: New antibacterial agents
38. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin and linezolid
39. Linezolid
40. New Gram-positive agents in nosocomial infection
41. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin)